Clinical Trial

HPV-Positive Oropharyngeal SCC

Study Description

Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Radiation - Radiation

70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)

Drug - Cisplatin

100 mg/m2 days 1, 22, 43 concurrently with RT

Drug - Durvalumab

Given in concurrent and adjuvant phase

Drug - Tremelimumab

ARM CLOSED TO ACCRUAL - 2019

Additional Information

Official Study Title

Randomized Phase II Study of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)

Clinical Trial ID

NCT03410615

ParticipAid ID

QdJ39e